=== PAGE 1 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its layout, spacing, and structure:

300x250

Animated Banner

                                                                                                                              Full Scrolling ISI
In a Real-World Study with nearly                                   With PFS, FN increased
11,000 patients                                                    by 31% vs Onpro®¹
                                                                                                                              (continued)
     **31%**       Pegfilgrastim                                        **31%**                                                         Nuclear Imaging
                   PFS resulted in a                                      **p = 0.01**                                                    • Increased hematopoietic activity of the bone marrow in
      **p = 0.01**   significantly higher                                                                                                       response to growth factor therapy has been associated with
                   risk of FN† on Onpro®¹                                                                                                       transient positive bone imaging changes. This should be
                                                                        †FN was defined as:                                                       considered when interpreting bone imaging results
Across all cycles of chemotherapy, the incidence of FN                  • Inpatient: Diagnosis of neutropenia AND (fever OR
associated with prefilled syringe (PFS) was 1.7% (n = 455)                infection)                                                      Most common adverse reactions
vs 1.3% (n = 126) for Neulasta® Onpro®.¹                                • Outpatient: Diagnosis of neutropenia AND (fever OR              • Bone pain
FN = febrile neutropenia.                                               AND prescribed antimicrobials)                                  • Pain in extremity

**Indication and Important Safety Information**                   **Indication and Important Safety Information**
Neulasta® (pegfilgrastim) is indicated to decrease the incidence   Neulasta® (pegfilgrastim) is indicated to decrease the incidence   Please see Neulasta® full Prescribing Information.
of infection, as manifested by febrile neutropenia, in patients  of infection, as manifested by febrile neutropenia, in patients
with non-myeloid malignancies receiving myelosuppressive          with non-myeloid malignancies receiving myelosuppressive          Special instructions for the on-body injector (OBI) for
anti-cancer drugs associated with a clinically significant       anti-cancer drugs associated with a clinically significant       Neulasta®
incidence of febrile neutropenia.                                incidence of febrile neutropenia.
                                                                                                                                    A healthcare provider must fill the on-body injector (OBI) with
**Prescribing Information**  **Instructions for Use**              **Prescribing Information**  **Instructions for Use**                Neulasta® using the co-packaged prefilled syringe and then
                                                                                                                                    apply the OBI to the patient's skin (abdomen or back of arm).
                                                                                                                                    The back of the arm may only be used if there is a caregiver
                                                                                                                                    available to monitor the status of the OBI. Approximately 27
                                                                                                                                    hours after the OBI is applied to the patient's skin, Neulasta®
                                                                                                                                    will be delivered over approximately 45 minutes. A healthcare
                                                                                                                                    provider may initiate administration with the OBI on the same
                                                                                                                                    day as the administration of cytotoxic chemotherapy, as long
                                                                                                                                    as the OBI delivers Neulasta® no less than 24 hours after the
                                                                                                                                    administration of cytotoxic chemotherapy.

                                                                                                                                    The prefilled syringe co-packaged in the Neulasta® Onpro® kit
                                                                                                                                    contains additional solution to compensate for liquid loss
                                                                                                                                    during delivery through the OBI. If this syringe is used for
                                                                                                                                    manual subcutaneous injection, the patient will receive an
                                                                                                                                    overdose. If the prefilled syringe for manual use is used with
                                                                                                                                    the OBI, the patient may receive less than the recommended
                                                                                                                                    dose.
                                                                                                                                    Do not use the OBI to deliver any other drug product except
                                                                                                                                    the Neulasta® prefilled syringe co-packaged with the OBI. Use
                                                                                                                                    of the OBI has not been studied in pediatric patients.

                                                                                                                                    The OBI should be applied to intact, non-irritated skin on the
                                                                                                                                    arm or abdomen.
                                                                                                                                    A missed dose could occur due to an OBI failure or leakage.
                                                                                                                                    Instruct patients using the OBI to notify their healthcare
                                                                                                                                    professional immediately in order to determine the need for a
                                                                                                                                    replacement dose of pegfilgrastim if they suspect that the
                                                                                                                                    device may not have performed as intended. If the patient
                                                                                                                                    misses a dose, a new dose should be administered by single
                                                                                                                                    prefilled syringe for manual use as soon as possible after
                                                                                                                                    detection.

                                                                                                                                    Review the Patient Information and Patient Instructions for Use
                                                                                                                                    with the patient and provide the instructions to the patient.
                                                                                                                                    Refer to the Healthcare Provider Instructions for Use for the
                                                                                                                                    OBI for full administration information.
                                                                                                                                    For any OBI problems, call Amgen at 1-800-772-6436 or
                                                                                                                                    1-844-MYNEULASTA (1-844-696-3852).

                                                                                                                                    References: 1. Data on file, Amgen; 2019. 2. Vogel CL, et al.
                                                                                                                                    J Clin Oncol. 2005;23(6):1178-1184.

                                                                                                                                    © 2020 Amgen Inc. All rights reserved. Not for reproduction.
                                                                                                                                    USA-003-80637 05-20

     **Neulasta® Onpro®**                                             **Neulasta® Onpro®**
     (pegfilgrastim) injection    kit                               (pegfilgrastim) injection    kit

     Choose Neulasta®                                                 Choose to help avoid
     Onpro®,                                                          next-day visits,

**Indication and Important Safety Information**                   **Indication and Important Safety Information**
Neulasta® (pegfilgrastim) is indicated to decrease the incidence   Neulasta® (pegfilgrastim) is indicated to decrease the incidence   **Indication and Important Safety Information**
of infection, as manifested by febrile neutropenia, in patients  of infection, as manifested by febrile neutropenia, in patients  Neulasta® (pegfilgrastim) is indicated to decrease the incidence
with non-myeloid malignancies receiving myelosuppressive          with non-myeloid malignancies receiving myelosuppressive          of infection, as manifested by febrile neutropenia, in patients
anti-cancer drugs associated with a clinically significant       anti-cancer drugs associated with a clinically significant       with non-myeloid malignancies receiving myelosuppressive
incidence of febrile neutropenia.                                incidence of febrile neutropenia.                                anti-cancer drugs associated with a clinically significant
                                                                                                                                    incidence of febrile neutropenia.
**Prescribing Information**  **Instructions for Use**              **Prescribing Information**  **Instructions for Use**                Neulasta® is not indicated for the mobilization of peripheral
                                                                                                                                    blood progenitor cells for hematopoietic stem cell
                                                                                                                                    transplantation.
                                                                                                                                    **Important Safety Information**
                                                                                                                                    **Contraindication**
                                                                                                                                    • Neulasta® is contraindicated in patients with a history of
                                                                                                                                      serious allergic reactions to pegfilgrastim or filgrastim
                                                                                                                                    • Reactions have included anaphylaxis
                                                                                                                                    **Splenic Rupture**
                                                                                                                                    • Splenic rupture, including fatal cases, can occur following the
                                                                                                                                      administration of Neulasta®
                                                                                                                                    • Evaluate for an enlarged or ruptured spleen in patients who
                                                                                                                                      report left upper abdominal or shoulder pain
                                                                                                                                    **Acute Respiratory Distress Syndrome (ARDS)**
                                                                                                                                    • ARDS has occurred in patients receiving Neulasta®
                                                                                                                                    • Evaluate patients who develop fever and lung infiltrates or
                                                                                                                                      respiratory distress after receiving Neulasta®
                                                                                                                                    • Discontinue Neulasta® in patients with ARDS
                                                                                                                                    **Serious Allergic Reactions**
                                                                                                                                    • Serious allergic reactions, including anaphylaxis can occur in
                                                                                                                                      patients receiving Neulasta®
                                                                                                                                    • Majority of events occurred upon initial exposure and can
                                                                                                                                      recur within days after discontinuation of initial anti-allergic
                                                                                                                                      treatment
                                                                                                                                    • Permanently discontinue Neulasta® in patients with serious
                                                                                                                                      allergic reactions
                                                                                                                                    **Allergies to Acrylics**
                                                                                                                                    • On-body injector (OBI) for Neulasta® uses acrylic adhesives
                                                                                                                                    • Patients who are allergic to acrylic adhesives may have a
                                                                                                                                      significant reaction
                                                                                                                                    **Use in Patients With Sickle Cell Disorders**
                                                                                                                                    • In patients with sickle cell trait or disease, sickle cell crisis, in
                                                                                                                                      some cases fatal, can occur in patients receiving Neulasta®
                                                                                                                                    • Discontinue Neulasta® if sickle cell crisis occurs
                                                                                                                                    **Glomerulonephritis**
                                                                                                                                    • Has occurred in patients receiving Neulasta®
                                                                                                                                    • Diagnoses based on a renal biopsy, hematuria, proteinuria, and
                                                                                                                                      azotemia
                                                                                                                                    • Generally events resolved after dose reduction or
                                                                                                                                      discontinuation of Neulasta®
                                                                                                                                    • If suspected, evaluate for cause and if cause is likely,
                                                                                                                                      consider dose-reduction or interruption of Neulasta®
                                                                                                                                    **Leukocytosis**
                                                                                                                                    • Increased white blood cell counts of 100 x 10⁹/L have been
                                                                                                                                      observed
                                                                                                                                    • Monitoring CBCs is recommended
                                                                                                                                    **Capillary Leak Syndrome (CLS)**
                                                                                                                                    • CLS has been reported after G-CSF administration, including
                                                                                                                                      Neulasta®
                                                                                                                                    • Characterized by hypotension, hypoalbuminemia, edema,
                                                                                                                                      and hemoconcentration
                                                                                                                                    • Episodes vary in frequency, severity, and may be life-
                                                                                                                                      threatening if treatment is delayed
                                                                                                                                    • Patients with symptoms of CLS should be closely monitored and
                                                                                                                                      receive standard symptomatic treatment, which may include
                                                                                                                                      intensive care
                                                                                                                                    **Potential for Tumor Growth Stimulatory Effects on
                                                                                                                                    Malignant Cells**
                                                                                                                                    • G-CSF receptor has been found on tumor cell lines
                                                                                                                                    • The possibility that pegfilgrastim acts as a growth factor for
                                                                                                                                      any tumor type, including myeloid malignancies and
                                                                                                                                      myelodysplasia, cannot be excluded
                                                                                                                                    **Potential Device Failures**
                                                                                                                                    • Missed or partial doses have been reported in patients
                                                                                                                                      using the on-body injector (OBI) due to the device not
                                                                                                                                      performing as intended
                                                                                                                                    • In the event of a missed or partial dose, patients may be at
                                                                                                                                      increased risk of events, such as neutropenia, febrile
                                                                                                                                      neutropenia and/or infection if the dose had been
                                                                                                                                      correctly delivered
                                                                                                                                    • Instruct patients to notify their healthcare professional
                                                                                                                                      immediately in order to determine the need for a
                                                                                                                                      replacement dose if they suspect that the device may not
                                                                                                                                      have performed as intended
                                                                                                                                    **Aortitis**
                                                                                                                                    • Aortitis has been reported in patients receiving Neulasta®. It
                                                                                                                                      may occur as early as the first week after start of therapy
                                                                                                                                    • Manifestations may include generalized signs and symptoms
                                                                                                                                      such as fever, abdominal pain, malaise, back pain, and
                                                                                                                                      increased inflammatory markers (e.g., c-reactive protein and
                                                                                                                                      ESR)
                                                                                                                                    • Consider aortitis in patients who develop these signs and
                                                                                                                                      symptoms without known etiology. Discontinue Neulasta® if
                                                                                                                                      aortitis is suspected
     **Neulasta® Onpro®**
     (pegfilgrastim) injection    kit

     Choose to let
     patients stay home.

Graphic and type scrolls up from bottom of frame         First frame text fades out; new copy slides in from     Graphic and type scroll out of the top of the frame      Previous frame text fades out and new text fades in
and fixes in place.                                     bottom of frame and fixes in place next to graphic.     as the logo and message slide in from the bottom         below fixed logo.
                                                                                                                and fix into place.

                                                                                                                              Amgen Inc.
                                                                                                                              One Amgen Center Drive
                                                                                                                              Thousand Oaks, CA 91320-1799
                                                                                                                              www.amgen.com

     **Pivotal Trial Study Design and Results²**                  myelosuppressive chemotherapy. The study included 35,856 cycles of
     Phase 3, multicenter, multinational, double-blind, placebo-controlled trial of  chemotherapy in which Neulasta® was administered (n = 9,395)
     patients with breast cancer (Neulasta® [n = 463] or placebo [n = 465]) receiving  and 26,461 PFS administrations¹.
     100 mg/m² docetaxel Q3W for up to 4 cycles. The key endpoint was the
     percentage of patients who developed FN (Neulasta® 1% versus placebo 17%,       • Patients were followed for 6 to 12 months following the start of the first
     P < 0.001). Also, secondary endpoints were lower for Neulasta®-treated            chemotherapy cycle. The study period was 1/1/16-9/30/18¹.
     patients as compared to placebo-treated patients (the incidence of
     hospitalization [1% versus 14%] and IV anti-infective use [2% versus 10%]).     • Data Source: MarketScan® Commercial Claims and Encounters/Medicare
     FN = temperature ≥ 38.2°C and absolute neutrophil count < 0.5 x 10⁹/L.            Supplemental and Coordination of Benefits Databases¹.
     Q3W = once every 3 weeks; IV = intravenous.

     **Real-World Study Design¹**                                  **Real-World Study Limitations¹**
     A retrospective study designed to compare the incidence of FN associated with    • Retrospective analysis that did not control for additional variables that may
     Neulasta® Onpro® vs Neulasta® PFS among patients receiving                        influence the incidence of FN
                                                                                     • Database was not sufficient to understand root causes for observed lower rate
                                                                                       of FN for patients receiving Onpro®.

                                                                     LEARN MORE

**Indication and Important Safety Information**                   **Indication and Important Safety Information**
Neulasta® (pegfilgrastim) is indicated to decrease the incidence   Neulasta® (pegfilgrastim) is indicated to decrease the incidence
of infection, as manifested by febrile neutropenia, in patients  of infection, as manifested by febrile neutropenia, in patients
with non-myeloid malignancies receiving myelosuppressive          with non-myeloid malignancies receiving myelosuppressive
anti-cancer drugs associated with a clinically significant       anti-cancer drugs associated with a clinically significant
incidence of febrile neutropenia.                                incidence of febrile neutropenia.

**Prescribing Information**  **Instructions for Use**              **Prescribing Information**  **Instructions for Use**

Logo and text fade out and scroll out of top of
frame as footnote copy scrolls in from the bottom,
and these next two frames will start to scroll at the
27th second. They will continue to scroll past the
30th second point till the material has run through.
And there will be a bar at the right for a user to go
back on the blue content on these two frames.
